A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100

Share:
Dr. John Kovach, the CEO and founder of Lixte Biotechnology Holdings, Inc., expressed excitement for his company’s first-in-class protein phosphatase inhibitor, LB-100 as a new addition to cancer treatment at the Benzinga Global Small Cap Business Conference on May 13, 2021.
Lixte Biotechnology (NASDAQ: LIXT), a drug discovery company, created and patented a series of novel drugs that enhance the effectiveness of standard anti-cancer therapy in a number of animal models.
More than 40 preclinical studies report that Lixte’s LB-100 increases the anti-tumor activity of standard chemotherapy, radiotherapy and immunotherapy without increasing toxicity.
Dr. Kovach noted that Lixte’s extensive international patent portfolio includes patents for LB-100 and its potential clinical applications based on lead compounds and some other drivers of those compounds. “We’re not aware of any competition at the moment, but we expect we’ll be getting some soon,” he said, “but we have quite a lead.”

Related Keywords

Minnesota , United States , Mayo Clinic In Rochester , John Kovach , Lixte Biotechnology Holdings , Lixte Biotechnology Holdings Inc , Us Oncology Network , Benzinga Global Small Cap Business Conference , Mayo Clinic , Myelodysplastic Syndromes , மினசோட்டா , ஒன்றுபட்டது மாநிலங்களில் , மயோ சிகிச்சையகம் இல் ரோசெஸ்டர் , ஜான் கோவாச் , எங்களுக்கு புற்றுநோயியல் வலைப்பின்னல் , மயோ சிகிச்சையகம் ,